Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Teleflex enters October with its short position retreating from September highs, yet the stock has shed 10% over the past month and the consensus remains firmly in Hold territory, leaving the BofA upgrade from ten days ago looking premature at current prices.
The lending market has loosened considerably since late August, and that shift is one of the cleaner stories in the data. Availability ran at roughly 380% in early September, meaning lenders had less than half a share free for every share already borrowed. Now availability is back above 747%, the lending pool has opened up substantially as short sellers trimmed positions. Short interest as a percentage of free float stands at 8.6%, down 13% from a month ago and down fractionally on the week. Borrowing costs have eased in parallel, dropping around 3% on the week to 0.51%. The ORTEX short score has drifted down from 55.3 on September 30 to 54.0, a modest but consistent move in the bears' retreat. The short score rank of 19 out of 100 confirms this is still a stock with meaningful short positioning relative to the universe, even after the recent reduction.
Options traders are leaning bullish, adding an interesting counterpoint to the cautious consensus. The put/call ratio has dropped to 0.19, well below its 20-day average of 0.27 and more than one standard deviation below the mean. Calls are dominating the book. That suggests options market participants are positioned for upside, which aligns with the bulls on the Street but sits awkwardly against a stock that has just posted its worst monthly performance in recent memory and trades nearly $30 below the mean analyst target of $155.
The Street itself remains split in a way that was covered in the previous note but has not resolved. BofA's Craig Bijou upgraded to Buy on September 28, lifting his target to $158 from $145, a notable move from a bellwether firm. Needham held Buy with a $170 target. Piper Sandler sits at Overweight with $169. Against that, seven of nine analysts remain at Hold, with targets from Truist at $150, UBS at $158, and Mizuho at $145. The mean target of $155 implies around 24% upside from the current $124.48 close, a gap that reflects genuine disagreement rather than a consensus call. The bull case rests on Freesolve's potential to expand PCI adoption and early clinical data from BIOMAG-I, which showed a 3.5% target lesion failure rate at four years with no cardiac deaths or scaffold thrombosis. The bear case is blunter: organic growth below 4%, new product launches underperforming, and margin pressure that could force a choice between profitability and restoring the topline. EPS momentum factor scores are strong, ranked in the 82nd to 88th percentile over 30 and 90 days, and the EPS surprise score ranks 88th. Those are genuine positives. But the analyst recommendation divergence score, ranked 94th, signals an unusually wide spread of views for this name, which rarely resolves quietly.
Institutional ownership is concentrated and relatively stable. BlackRock holds 12.8% as the largest single position, with Janus Henderson at 10.3% and T. Rowe Price at 7.6%. Janus Henderson filed a 13G amendment in September showing its stake has grown from 9.4% to 10.3%, a directional vote of confidence worth noting. Dimensional added 155,000 shares in the period ending September 30. On the other side, Baupost trimmed 186,000 shares as of June 30, a meaningful reduction from one of the more considered holders in the register. Insider activity in the recent window has been limited to compensation grants and tax withholding transactions with no open-market purchases or sales, so there is no directional signal from the executive suite heading into November.
Peers have had a mixed week. RMD gained 2.2% on the week while BSX fell 4.7%, and SOLV dropped 2.6%. TFX's 0.4% weekly decline is modest by comparison, but the 10% monthly drawdown puts it on the wrong end of the sector performance table. The November 5 earnings date is now 28 days out, and whether the stock can close the gap between its current price and the analyst target cluster will depend on what management says about procedural volume trends and the margin trajectory in Q3.
See the live data behind this article on ORTEX.
Open TFX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
